Drug candidates are compounds that have progressed beyond early screening and are being evaluated more intensively for safety, efficacy, and developability. They sit between initial hits and fully developed medicines. This term is important because AI tools often claim to “optimise drug candidates,” which refers to fine‑tuning properties like potency, selectivity, or pharmacokinetics before committing to costly preclinical and clinical programmes.